TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27815483

Group type: EXPERIMENTAL
Intervention: Autologous Serum (AS) eye drops
Number of subjects: 24

Group type: COMPARATOR
Intervention: Artificial Tear (AT) therapy
Number of subjects: 24
Study: 24979446

Group type: EXPERIMENTAL
Intervention: Once‐daily oral tenofovir disoproxil fumarate (TDF) or FTC‐TDF
Number of subjects: 1522

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1522

Group type: EXPERIMENTAL
Intervention: Once‐daily oral tenofovir-based PrEP
Number of subjects: 1522
Study: 22653255

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate high-protein diet
Number of subjects: 307

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 307
Study: 19270357

Group type: EXPERIMENTAL
Intervention: Isoflurane preconditioning (1.0 minimum alveolar concentration end-tidal, approximately 1.1% to 1.2%) administered for 30 min followed by a 15 min washout period before CPB.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no isoflurane inhalation).
Number of subjects: 30
Study: 17479540

Group type: COMPARATOR
Intervention: Metformin hydrochloride extended-release (MXR) 1000 mg single dose
Number of subjects: 42

Group type: COMPARATOR
Intervention: Metformin hydrochloride extended-release (MXR) 1000 mg/d for 9 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Metformin hydrochloride immediate-release (MIR) 1000 mg single dose
Number of subjects: 42

Group type: COMPARATOR
Intervention: Metformin hydrochloride immediate-release (MIR) 1000 mg/d for 14 days
Number of subjects: 42
Study: 14766692

Group type: EXPERIMENTAL
Intervention: McCoy straight blade laryngoscope
Number of subjects: 40

Group type: COMPARATOR
Intervention: Miller curved blade laryngoscope
Number of subjects: 40
Study: 12119202

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg per day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg per day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 11
Study: 9402378

Group type: EXPERIMENTAL
Intervention: Ganciclovir plus IVIG
Number of subjects: 56

Group type: COMPARATOR
Intervention: IVIG alone
Number of subjects: 56
Study: 8496328

Group type: EXPERIMENTAL
Intervention: GH therapy (0.125 IU/kg.week for the first 4 weeks and subsequently at 0.25 IU/kg.week for 1 year)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GH therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 12
Study: 2879882

Group type: EXPERIMENTAL
Intervention: Single-blind placebo over a 2-week period
Number of subjects: 20

Group type: COMPARATOR
Intervention: Double-blind placebo over an 8-week period
Number of subjects: 20
Study: 31230988

Group type: EXPERIMENTAL
Intervention: Movement System Impairment-Based classification treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (other forms of exercise)
Number of subjects: 0
Study: 31393414

Group type: EXPERIMENTAL
Intervention: Low to moderate intensity exercise program (LMIEP)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise program (MICEP)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Non-exercised group (Control)
Number of subjects: 69
Study: 28006108

Group type: EXPERIMENTAL
Intervention: Digitoxin 0.1 mg daily for 28 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Digitoxin 0.05 mg daily for 28 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 26449209

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1 mA for 10 min)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (1 mA for 10 min)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham stimulation (10 min)
Number of subjects: 19
Study: 24637543

Group type: EXPERIMENTAL
Intervention: EFV (efavirenz)
Number of subjects: 269

Group type: COMPARATOR
Intervention: ATV/r (atazanavir-ritonavir)
Number of subjects: 269

Group type: COMPARATOR
Intervention: ABC/3TC (abacavir-lamivudine)
Number of subjects: 269

Group type: COMPARATOR
Intervention: TDF/FTC (tenofovir DF-emtricitabine)
Number of subjects: 269
Study: 21926600

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony stimulating factor (250 μg/M)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 19153503

Group type: EXPERIMENTAL
Intervention: Pegvisomant therapy
Number of subjects: 469
Study: 17300305

Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 20

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 20
Study: 15446658

Group type: EXPERIMENTAL
Intervention: Same visual field presentation of primes and targets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different visual field presentation of primes and targets
Number of subjects: 0
Study: 11177147

Group type: EXPERIMENTAL
Intervention: Central venous catheters cultured for clinical suspicion of infection
Number of subjects: 260
Study: 9764028

Group type: EXPERIMENTAL
Intervention: Standardized teaching plan with quarterly telephone calls for smoking cessation and diet reinforcement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardized teaching plan without telephone reinforcement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups received standardized teaching plan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smokers vs nonsmokers
Number of subjects: 0
Study: 7933823

Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (0.08 mg/kg)
Number of subjects: 20
Study: 3234411

Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg (60 mg q.i.d.)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Metoprolol 200 mg (100 mg b.i.d.)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 33

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 33
Study: 2058318

Group type: EXPERIMENTAL
Intervention: Ketanserin (S2-receptor blocker) with concurrent physiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 0
Study: 332188

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid combined with fentonium bromide (125 mg and 20 mg respectively, 3-4 capsules daily for 14 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Biliary acid alone
Number of subjects: 30
Study: 20535582

Group type: EXPERIMENTAL
Intervention: Dixiong Decoction
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (commonly used herbal decoction)
Number of subjects: 46
Study: 31413691

Group type: EXPERIMENTAL
Intervention: Operative treatment with irrigation and debridement
Number of subjects: 46

Group type: COMPARATOR
Intervention: Nonoperative treatment with antibiotics and wound care
Number of subjects: 46
Study: 27443414

Group type: EXPERIMENTAL
Intervention: TAS-102 (n=80)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo (n=32)
Number of subjects: 112
Study: 25026454

Group type: COMPARATOR
Intervention: 5LEU (23/5/180/30 g of protein/leucine/carbohydrate/fat)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 15LEU (70/15/180/30 g of protein/leucine/carbohydrate/fat)
Number of subjects: 12

Group type: COMPARATOR
Intervention: CON (0/0/274/30 g of carbohydrate/fat)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 15LEU
Number of subjects: 12
Study: 23852069

Group type: EXPERIMENTAL
Intervention: Reciproc and Pathfile
Number of subjects: 88

Group type: COMPARATOR
Intervention: ProTaper and Pathfile
Number of subjects: 88

Group type: COMPARATOR
Intervention: Rotary ProTaper
Number of subjects: 88
Study: 22018535

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group intervention
Number of subjects: 0
Study: 19858413

Group type: EXPERIMENTAL
Intervention: TAXUS EXPRESS paclitaxel‐eluting stents (PES)
Number of subjects: 464

Group type: COMPARATOR
Intervention: EXPRESS bare metal stents (BMS)
Number of subjects: 464
Study: 16925565

Group type: EXPERIMENTAL
Intervention: Study Patients (SPs)
Number of subjects: 512

Group type: COMPARATOR
Intervention: Nonstudy Patients (NSPs)
Number of subjects: 512
Study: 14701969

Group type: COMPARATOR
Intervention: Oxytetracycline
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 2
Study: 11551141

Group type: EXPERIMENTAL
Intervention: Calcium (CaCl2) 15 mg/kg b.w. administered intravenously
Number of subjects: 43

Group type: COMPARATOR
Intervention: Disodium EDTA 5 mg/kg b.w. administered intravenously
Number of subjects: 43
Study: 9381521

Group type: EXPERIMENTAL
Intervention: Snoezelen intervention in a specially furnished room
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard activities in the living room (Control)
Number of subjects: 16
Study: 8492923

Group type: EXPERIMENTAL
Intervention: Vigorous exercise started 1 hour after LD ingestion
Number of subjects: 10

Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 10
Study: 3794392

Group type: EXPERIMENTAL
Intervention: UVB irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UVA irradiation
Number of subjects: 0
Study: 30374603

Group type: EXPERIMENTAL
Intervention: Vitamin D therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D treatment in children
Number of subjects: 0
Study: 28538134

Group type: EXPERIMENTAL
Intervention: Cannabidiol oral solution at a dose of 20 mg per kilogram of body weight per day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cannabidiol
Number of subjects: 120
Study: 23838836

Group type: EXPERIMENTAL
Intervention: Surgery-first approach without presurgical orthodontic treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard orthognathic surgery
Number of subjects: 56
Study: 23013143

Group type: EXPERIMENTAL
Intervention: Hypoxia (16.5 ± 0.5% O(2))
Number of subjects: 11

Group type: COMPARATOR
Intervention: Air
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Hypoxia (with drop in SpO(2) > 10%)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Hypoxia and exercise
Number of subjects: 11
Study: 21825028

Group type: EXPERIMENTAL
Intervention: 2 weeks of lower limb cast immobilisation
Number of subjects: 378
Study: 18496276

Group type: EXPERIMENTAL
Intervention: Hemocontrol Biofeedback System (HBS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best clinical practices
Number of subjects: 0
Study: 16567837

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 2980

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 2980

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2980
Study: 12394920

Group type: EXPERIMENTAL
Intervention: Chromium release assay
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Flow cytometric assay
Number of subjects: 20
Study: 10439008

Group type: EXPERIMENTAL
Intervention: Sequential PCRs (group I, n = 30)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Primed in situ labeling (PRINS) before five sequential PCRs (group II, n = 10)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Staining with hematoxylin before performing five sequential PCRs (group III, n = 11)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Preamplification of whole DNAs by degenerate oligonucleotide primer (DOP) before performing PCR (group IV)
Number of subjects: 58
Study: 7995742

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (120 mg/kg) and total body irradiation (1320 Gy in eight fractions over 4 days) (CY/TBI)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg) (BU/CY)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CY/TBI
Number of subjects: 35

Group type: COMPARATOR
Intervention: BU/CY
Number of subjects: 35
Study: 2312805

Group type: EXPERIMENTAL
Intervention: Topical cyclosporine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 10
Study: 375369

Group type: EXPERIMENTAL
Intervention: Radioisotope synoviorthesis with 90Y (4 mCi)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radioisotope synoviorthesis with 198Au or 186Rh
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline + prednisolone acetate (control)
Number of subjects: 0
Study: 31343196

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 912

Group type: COMPARATOR
Intervention: Intensive Outpatient Treatment (IOP)
Number of subjects: 912
Study: 29903423

Group type: EXPERIMENTAL
Intervention: xylazine and butorphanol administered intravenously (IV)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: detomidine and butorphanol administered IV
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: xylazine administered IV and lidocaine topically
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: detomidine administered IV and lidocaine topically
Number of subjects: 8

Group type: COMPARATOR
Intervention: no analgesia or sedation (control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: butorphanol
Number of subjects: 8
Study: 26545288

Group type: EXPERIMENTAL
Intervention: Anger Coping Programme based on cognitive behavioural techniques
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 62
Study: 25298243

Group type: EXPERIMENTAL
Intervention: Percutaneous assisted approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anterolateral approach
Number of subjects: 0
Study: 22918856

Group type: EXPERIMENTAL
Intervention: Test 250 mg metronidazole immediate release formulation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Reference 250 mg metronidazole immediate release formulation
Number of subjects: 22
Study: 20150293

Group type: EXPERIMENTAL
Intervention: High protein diet with resistance training (HP+RT)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control diet with resistance training (CON+RT)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: High protein diet (HP)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control diet (CON)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Overall reduction across all groups
Number of subjects: 83
Study: 18160750

Group type: EXPERIMENTAL
Intervention: Category-1 regimen for PTB
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Category-1 regimen for DM-TB
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Category-1 regimen for HIV-TB
Number of subjects: 278
Study: 16136943

Group type: EXPERIMENTAL
Intervention: Integrated treatment group (radiotherapy + Chinese herbal drugs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (simple radiotherapy)
Number of subjects: 60
Study: 12396855

Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Face-to-face consultation
Number of subjects: 65

Group type: COMPARATOR
Intervention: General physicians
Number of subjects: 65
Study: 10581644

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Isradipine pretreatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 18
Study: 7568433

Group type: EXPERIMENTAL
Intervention: Amiloride treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Organic Na+ salts and Li+ salts
Number of subjects: 0

Group type: COMPARATOR
Intervention: NaCl
Number of subjects: 0
Study: 1970907

Group type: EXPERIMENTAL
Intervention: Acrivastine 8 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pseudoephedrine 60 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acrivastine 8 mg plus Pseudoephedrine 60 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 91478

Group type: EXPERIMENTAL
Intervention: Diffuse field stimulation in 44 MS patients
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Analysis of central and peripheral retina in 41 MS patients
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Retesting of 20 subjects with normal/slightly altered full field VEPs
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Correlation of CPLD with clinical involvement
Number of subjects: 85
Study: 30824559

Group type: EXPERIMENTAL
Intervention: ODM‐101/65 (65 mg carbidopa, 75-150 mg levodopa, 200 mg entacapone)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: ODM‐101/105 (105 mg carbidopa, 75-150 mg levodopa, 200 mg entacapone)
Number of subjects: 117

Group type: COMPARATOR
Intervention: LCE (standard combination of 4:1 levodopa/carbidopa with 200 mg entacapone)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: ODM‐101/65
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: ODM‐101/105
Number of subjects: 117

Group type: COMPARATOR
Intervention: LCE
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: ODM‐101/65 and ODM‐101/105
Number of subjects: 117
Study: 28738338

Group type: EXPERIMENTAL
Intervention: Timed Up and Go test (TUG) real (TUGr)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Timed Up and Go test (TUG) imagined (TUGi)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Trail Making Test part B (TMT B)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Trail Making Test A/B ratio (TMT B/A)
Number of subjects: 52
Study: 27451343

Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 683

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 683
Study: 24092769

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (11.1g·kg‐1)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Calorie-matched low carbohydrate diet (2.1 g·kg‐1)
Number of subjects: 9
Study: 22038392

Group type: EXPERIMENTAL
Intervention: Self-rated QOL using the QOL-AD scale
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Caregiver-rated QOL-AD scores
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Caregiver-rated ADRQL scores
Number of subjects: 254
Study: 19667948

Group type: COMPARATOR
Intervention: P/CsA
Number of subjects: 113

Group type: COMPARATOR
Intervention: P/MPS
Number of subjects: 113

Group type: COMPARATOR
Intervention: P/EVL
Number of subjects: 113
Study: 17461874

Group type: EXPERIMENTAL
Intervention: Home orthostatic self-training (daily sessions for 7 days a week for 4 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Home orthostatic self-training
Number of subjects: 42
Study: 15932835

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 2.5 mg/d
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 5.0 mg/d
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 10 mg/d
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg/d
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 30 mg/d
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 40 mg/d
Number of subjects: 497

Group type: COMPARATOR
Intervention: Conjugated estrogens (0.625 mg)/medroxyprogesterone acetate (2.5 mg) (active control)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 497
Study: 11956508

Group type: EXPERIMENTAL
Intervention: 125 mg bosentan twice a day for 10 days plus 2.5 mg glyburide twice a day on days 6 to 10
Number of subjects: 12

Group type: COMPARATOR
Intervention: 2.5 mg glyburide twice a day for 10 days plus 125 mg bosentan twice a day on days 6 to 10
Number of subjects: 12
Study: 9605682

Group type: EXPERIMENTAL
Intervention: Desflurane (anesthesia at 0.5, 1, and 1.5 MAC)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Isoflurane (anesthesia at 0.5, 1, and 1.5 MAC)
Number of subjects: 17
Study: 1992536

Group type: COMPARATOR
Intervention: 7‐3 (cytarabine 100 mg/m2/d days 1 to 7 and daunorubicin 50 mg/m2/d days 1 to 3)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: 7‐3‐7 (7‐3 plus etoposide 75 mg/m2/d days 1 to 7)
Number of subjects: 264

Group type: COMPARATOR
Intervention: 7‐3
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: 7‐3‐7
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: 7‐3 and 7‐3‐7
Number of subjects: 264
Study: 6340300

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 250 mg i.v. 2 hours before cis-platinum administration
Number of subjects: 90

Group type: COMPARATOR
Intervention: Torecan
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (10 ml saline)
Number of subjects: 90
Study: 30829918

Group type: EXPERIMENTAL
Intervention: Non-Alcoholic Fatty Liver Disease (NAFLD)
Number of subjects: 324
Study: 29367035

Group type: EXPERIMENTAL
Intervention: Multicolour inking (arm A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Monocolour inking (arm B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall R1 resection rate
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Anterior surface margin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Superior mesenteric artery margin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pancreatic remnant margin
Number of subjects: 50
Study: 27188899

Group type: COMPARATOR
Intervention: Riboflavin supplementation at doses of 0.2, 0.4, 0.6, 0.8, or 1.0 mg daily for 6 weeks
Number of subjects: 78

Group type: COMPARATOR
Intervention: Riboflavin supplementation at doses of 0.6 mg/d and above
Number of subjects: 78

Group type: COMPARATOR
Intervention: Riboflavin supplementation
Number of subjects: 78
Study: 23714686

Group type: EXPERIMENTAL
Intervention: Homeopathic syrup
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 22486138

Group type: EXPERIMENTAL
Intervention: Preoperative volume loading (lactated Ringer 10 ml/kg before induction of general anesthesia)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no preoperative volume loading)
Number of subjects: 30
Study: 20858770

Group type: EXPERIMENTAL
Intervention: Alvimopan 12 mg
Number of subjects: 199

Group type: COMPARATOR
Intervention: Historical control
Number of subjects: 199
Study: 18197496

Group type: EXPERIMENTAL
Intervention: Young group (under 40 years old)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Old group (over 65 years old)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Young group (under 40 years old) with same TNM stage
Number of subjects: 301

Group type: COMPARATOR
Intervention: Old group (over 65 years old) with same TNM stage
Number of subjects: 301
Study: 16365696

Group type: EXPERIMENTAL
Intervention: Antioxidant supplemented (90 days' diet supplementation with 500 mg/day vitamin E and 30 mg/day beta‐carotene, and the last 15 days also with 1 g/day vitamin C)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 15